Annual CFO
$27.01 M
+$42.84 M+270.65%
December 31, 2023
Summary
- As of February 7, 2025, PBYI annual cash flow from operations is $27.01 million, with the most recent change of +$42.84 million (+270.65%) on December 31, 2023.
- During the last 3 years, PBYI annual CFO has risen by +$26.24 million (+3394.05%).
- PBYI annual CFO is now at all-time high.
Performance
PBYI Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
$11.04 M
+$10.01 M+974.78%
September 30, 2024
Summary
- As of February 7, 2025, PBYI quarterly cash flow from operations is $11.04 million, with the most recent change of +$10.01 million (+974.78%) on September 30, 2024.
- Over the past year, PBYI quarterly CFO has increased by +$423.00 thousand (+3.98%).
- PBYI quarterly CFO is now -75.05% below its all-time high of $44.25 million, reached on June 30, 2019.
Performance
PBYI Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
$33.77 M
+$423.00 K+1.27%
September 30, 2024
Summary
- As of February 7, 2025, PBYI TTM cash flow from operations is $33.77 million, with the most recent change of +$423.00 thousand (+1.27%) on September 30, 2024.
- Over the past year, PBYI TTM CFO has increased by +$9.53 million (+39.32%).
- PBYI TTM CFO is now -5.18% below its all-time high of $35.61 million, reached on March 31, 2024.
Performance
PBYI TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
PBYI Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +270.6% | +4.0% | +39.3% |
| 3 y3 years | +3394.1% | +179.6% | +194.6% |
| 5 y5 years | +212.1% | +179.6% | +194.6% |
PBYI Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +270.6% | -36.0% | +141.0% | -5.2% | +194.6% |
| 5 y | 5-year | at high | +270.6% | -36.0% | +141.0% | -5.2% | +194.6% |
| alltime | all time | at high | +115.7% | -75.0% | +120.1% | -5.2% | +119.0% |
Puma Biotechnology Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $11.04 M(+974.8%) | $33.77 M(+1.3%) |
| Jun 2024 | - | $1.03 M(-90.9%) | $33.34 M(-6.4%) |
| Mar 2024 | - | $11.25 M(+7.6%) | $35.61 M(+31.9%) |
| Dec 2023 | $27.01 M(-270.7%) | $10.46 M(-1.5%) | $27.01 M(+11.4%) |
| Sep 2023 | - | $10.62 M(+222.1%) | $24.24 M(-21.5%) |
| Jun 2023 | - | $3.30 M(+24.7%) | $30.88 M(+125.2%) |
| Mar 2023 | - | $2.64 M(-65.6%) | $13.71 M(-186.6%) |
| Dec 2022 | -$15.83 M(-176.6%) | $7.68 M(-55.5%) | -$15.83 M(-45.3%) |
| Sep 2022 | - | $17.26 M(-224.4%) | -$28.95 M(-18.9%) |
| Jun 2022 | - | -$13.87 M(-48.4%) | -$35.71 M(+63.0%) |
| Mar 2022 | - | -$26.89 M(+394.8%) | -$21.91 M(-206.1%) |
| Dec 2021 | $20.65 M(+2571.4%) | -$5.43 M(-151.8%) | $20.65 M(+1.0%) |
| Sep 2021 | - | $10.50 M(<-9900.0%) | $20.45 M(+75.2%) |
| Jun 2021 | - | -$74.00 K(-100.5%) | $11.67 M(-58.3%) |
| Mar 2021 | - | $15.66 M(-377.9%) | $27.97 M(+3518.9%) |
| Dec 2020 | $773.00 K(-96.5%) | -$5.63 M(-427.6%) | $773.00 K(-90.3%) |
| Sep 2020 | - | $1.72 M(-89.4%) | $7.97 M(-857.3%) |
| Jun 2020 | - | $16.23 M(-240.6%) | -$1.05 M(-103.9%) |
| Mar 2020 | - | -$11.54 M(-836.9%) | $26.97 M(+20.5%) |
| Dec 2019 | $22.38 M(-192.8%) | $1.57 M(-121.4%) | $22.38 M(-19.7%) |
| Sep 2019 | - | -$7.31 M(-116.5%) | $27.86 M(-0.2%) |
| Jun 2019 | - | $44.25 M(-374.3%) | $27.90 M(-182.1%) |
| Mar 2019 | - | -$16.13 M(-328.9%) | -$33.98 M(+41.0%) |
| Dec 2018 | -$24.11 M(-86.0%) | $7.05 M(-197.0%) | -$24.11 M(-63.9%) |
| Sep 2018 | - | -$7.26 M(-58.8%) | -$66.76 M(-41.6%) |
| Jun 2018 | - | -$17.64 M(+182.1%) | -$114.41 M(-19.8%) |
| Mar 2018 | - | -$6.25 M(-82.4%) | -$142.68 M(-17.3%) |
| Dec 2017 | -$172.47 M(+21.7%) | -$35.61 M(-35.1%) | -$172.47 M(-3.0%) |
| Sep 2017 | - | -$54.91 M(+19.6%) | -$177.82 M(+12.7%) |
| Jun 2017 | - | -$45.91 M(+27.4%) | -$157.81 M(+10.6%) |
| Mar 2017 | - | -$36.04 M(-12.0%) | -$142.70 M(+0.7%) |
| Dec 2016 | -$141.69 M | -$40.96 M(+17.4%) | -$141.69 M(+5.9%) |
| Sep 2016 | - | -$34.89 M(+13.2%) | -$133.76 M(-1.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2016 | - | -$30.81 M(-12.0%) | -$135.74 M(-2.7%) |
| Mar 2016 | - | -$35.03 M(+6.0%) | -$139.47 M(-9.7%) |
| Dec 2015 | -$154.47 M(+100.1%) | -$33.03 M(-10.4%) | -$154.47 M(+10.4%) |
| Sep 2015 | - | -$36.87 M(+6.7%) | -$139.90 M(+9.9%) |
| Jun 2015 | - | -$34.55 M(-30.9%) | -$127.35 M(+15.6%) |
| Mar 2015 | - | -$50.02 M(+171.0%) | -$110.18 M(+42.7%) |
| Dec 2014 | -$77.20 M(+40.2%) | -$18.46 M(-24.1%) | -$77.20 M(+6.8%) |
| Sep 2014 | - | -$24.32 M(+40.0%) | -$72.32 M(+20.5%) |
| Jun 2014 | - | -$17.37 M(+1.9%) | -$60.01 M(+11.9%) |
| Mar 2014 | - | -$17.05 M(+25.5%) | -$53.61 M(-2.6%) |
| Dec 2013 | -$55.05 M(+25.1%) | -$13.58 M(+13.0%) | -$55.05 M(-16.9%) |
| Sep 2013 | - | -$12.01 M(+9.5%) | -$66.28 M(+7.1%) |
| Jun 2013 | - | -$10.97 M(-40.6%) | -$61.91 M(+3.7%) |
| Mar 2013 | - | -$18.48 M(-25.5%) | -$59.71 M(+35.7%) |
| Dec 2012 | -$44.01 M(+2312.9%) | -$24.81 M(+224.6%) | -$44.01 M(+111.2%) |
| Sep 2012 | - | -$7.64 M(-12.9%) | -$20.84 M(+56.2%) |
| Jun 2012 | - | -$8.77 M(+215.0%) | -$13.34 M(+189.8%) |
| Mar 2012 | - | -$2.79 M(+69.7%) | -$4.61 M(+152.5%) |
| Dec 2011 | -$1.82 M(>+9900.0%) | -$1.64 M(+1045.8%) | -$1.82 M(+927.5%) |
| Sep 2011 | - | -$143.20 K(+297.8%) | -$177.50 K(+373.3%) |
| Jun 2011 | - | -$36.00 K(+823.1%) | -$37.50 K(+861.5%) |
| Mar 2011 | - | -$3900.00(-169.6%) | -$3900.00(-44.3%) |
| Dec 2010 | -$7000.00(-58.3%) | $5600.00(-275.0%) | -$7000.00(-48.5%) |
| Sep 2010 | - | -$3200.00(+33.3%) | -$13.60 K(-15.0%) |
| Jun 2010 | - | -$2400.00(-65.7%) | -$16.00 K(0.0%) |
| Mar 2010 | - | -$7000.00(+600.0%) | -$16.00 K(-4.8%) |
| Dec 2009 | -$16.80 K(+42.4%) | -$1000.00(-82.1%) | -$16.80 K(-6.7%) |
| Sep 2009 | - | -$5600.00(+133.3%) | -$18.00 K(+23.3%) |
| Jun 2009 | - | -$2400.00(-69.2%) | -$14.60 K(-3.3%) |
| Mar 2009 | - | -$7800.00(+254.5%) | -$15.10 K(+28.0%) |
| Dec 2008 | -$11.80 K | -$2200.00(0.0%) | -$11.80 K(+22.9%) |
| Sep 2008 | - | -$2200.00(-24.1%) | -$9600.00(+29.7%) |
| Jun 2008 | - | -$2900.00(-35.6%) | -$7400.00(+64.4%) |
| Mar 2008 | - | -$4500.00 | -$4500.00 |
FAQ
- What is Puma Biotechnology annual cash flow from operations?
- What is the all time high annual CFO for Puma Biotechnology?
- What is Puma Biotechnology annual CFO year-on-year change?
- What is Puma Biotechnology quarterly cash flow from operations?
- What is the all time high quarterly CFO for Puma Biotechnology?
- What is Puma Biotechnology quarterly CFO year-on-year change?
- What is Puma Biotechnology TTM cash flow from operations?
- What is the all time high TTM CFO for Puma Biotechnology?
- What is Puma Biotechnology TTM CFO year-on-year change?
What is Puma Biotechnology annual cash flow from operations?
The current annual CFO of PBYI is $27.01 M
What is the all time high annual CFO for Puma Biotechnology?
Puma Biotechnology all-time high annual cash flow from operations is $27.01 M
What is Puma Biotechnology annual CFO year-on-year change?
Over the past year, PBYI annual cash flow from operations has changed by +$42.84 M (+270.65%)
What is Puma Biotechnology quarterly cash flow from operations?
The current quarterly CFO of PBYI is $11.04 M
What is the all time high quarterly CFO for Puma Biotechnology?
Puma Biotechnology all-time high quarterly cash flow from operations is $44.25 M
What is Puma Biotechnology quarterly CFO year-on-year change?
Over the past year, PBYI quarterly cash flow from operations has changed by +$423.00 K (+3.98%)
What is Puma Biotechnology TTM cash flow from operations?
The current TTM CFO of PBYI is $33.77 M
What is the all time high TTM CFO for Puma Biotechnology?
Puma Biotechnology all-time high TTM cash flow from operations is $35.61 M
What is Puma Biotechnology TTM CFO year-on-year change?
Over the past year, PBYI TTM cash flow from operations has changed by +$9.53 M (+39.32%)